http://orcid.org/0000-0003-3085-7147
References
- Mancini M, Yarden Y. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Semin Cell Dev Biol. 2016;50:164–176.
- Wang D, Pan H, Wang Y. T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib. Leuk Lymphoma. 2017;58:1733–1735.
- Modugno M, Casale E, Soncini C, et al. Crystal structure of the T315I Abl mutant in complex with the Aurora kinases inhibitor PHA-739358. Cancer Res. 2007;67:7987–7990.
- Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias (supplementary index). N Engl J Med. 2013;369:1–52.
- How GF, Müller MC, Lim LC. Acquisition of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient. Leuk Res. 2012;36:e20–e21.
- Miller GD, Bruno BJ, Lim CS. Resistant mutations in CML and Ph + ALL – role of ponatinib. Biol Targets Ther. 2014;8:243–254.
- Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070–1079.
- Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18:401–408.
- Mallampati S, Leng X, Ma H, et al. Tyrosine kinase inhibitors induce mesenchymal stem cell – mediated resistance in BCR-ABL 1 acute lymphoblastic leukemia. Blood. 2015;125:2968–2974.
- Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell. 2014;26:428–442.
- Parker WT, Yeung DTO, Yeoman AL, et al. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 2016;127:1870–1880.
- Deininger MW, Hodgson JG, Shah NP, et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016;127:703–712.